Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P08100

UPID:
OPSD_HUMAN

ALTERNATIVE NAMES:
Opsin-2

ALTERNATIVE UPACC:
P08100; Q16414; Q2M249

BACKGROUND:
The protein Rhodopsin, known alternatively as Opsin-2, is integral to the visual process, especially under low light. It ensures the viability of photoreceptor cells and is involved in the initial steps of the visual signal transduction pathway. The light-induced change of 11-cis-retinal within Rhodopsin to all-trans-retinal is a critical trigger for visual signal processing, leading to the perception of light and images.

THERAPEUTIC SIGNIFICANCE:
Given its crucial role in vision, mutations in Rhodopsin are associated with debilitating visual disorders such as Retinitis pigmentosa 4 and congenital stationary night blindness. The exploration of Rhodopsin's function and its pathways offers promising avenues for developing targeted therapies for these visual impairments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.